Literature DB >> 25894392

Increase in nonhepatic diagnoses among persons with hepatitis C hospitalized for any cause, United States, 2004-2011.

X Tong1, P R Spradling1.   

Abstract

Although persons with hepatitis C virus (HCV) infection may experience nonhepatic illnesses, little is known about the frequency of and trends in such conditions in a population-based sample of HCV-infected persons. Using hospitalization data collected during 2004-2011 from the Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project, we examined trends in comorbidities among all hospitalizations that included either a principal or secondary HCV diagnostic code (i.e., HCV was not necessarily the cause for hospitalization). We also compared comorbidities among all persons aged 45-64 years hospitalized with and without principal or secondary HCV diagnostic codes. The estimated number of hospitalizations among persons with HCV infection increased from 850,490 in 2004-2005 to 1,178,633 in 2010-2011; mean age at hospitalization was 50 years in 2004-2005 and 52.5 years in 2010-2011. There were significant increases in the prevalence of most medical and psychiatric comorbidities; the largest were for lipid disorders, chronic kidney disease and obesity. Among HCV-infected aged 45-64 persons hospitalized for any cause, the prevalence of alcohol /substance abuse, mental disorders, chronic kidney disease, pneumonia, hepatitis B virus infection and HIV infection were significantly higher than those aged 45-64 persons hospitalized without HCV infection (P < 0.001 for all). The prevalence of cryoglobulinaemia, vasculitis, nephrotic syndrome or membranoproliferative glomerulonephritis and porphyria cutanea tarda among hospitalizations with HCV infection was consistently low during the study period (i.e., <0.5%). The increase we observed in nonhepatic comorbidities associated with a high risk of HCV-related complications has important implications for the current HCV treatment recommendations in a greatly expanded treatment population. Published 2015. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  healthcare cost and utilization project; international classification of diseases, 9th revision, clinical modification; morbidity; nationwide inpatient sample; treatment guidelines

Mesh:

Year:  2015        PMID: 25894392      PMCID: PMC6743325          DOI: 10.1111/jvh.12414

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  11 in total

Review 1.  Viral-Associated GN: Hepatitis C and HIV.

Authors:  Warren L Kupin
Journal:  Clin J Am Soc Nephrol       Date:  2016-10-24       Impact factor: 8.237

2.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  Infection       Date:  2018-09-25       Impact factor: 3.553

3.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  J Nephrol       Date:  2018-09-25       Impact factor: 3.902

4.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  Intern Emerg Med       Date:  2018-09-25       Impact factor: 3.397

5.  Prevalence of Renal Impairment and Associated Conditions Among HCV-Infected Persons in the Chronic Hepatitis Cohort Study (CHeCS).

Authors:  Anne C Moorman; Xin Tong; Philip R Spradling; Loralee B Rupp; Stuart C Gordon; Mei Lu; Eyasu H Teshale; Joseph A Boscarino; Connie M Trinacty; Mark A Schmidt; Fujie Xu; Scott D Holmberg
Journal:  Dig Dis Sci       Date:  2016-05-23       Impact factor: 3.199

6.  Patterns of Healthcare Utilization Among Veterans Infected With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) and Coinfected With HIV/HCV: Unique Burdens of Disease.

Authors:  Shereen Katrak; Lawrence P Park; Christopher Woods; Andrew Muir; Charles Hicks; Susanna Naggie
Journal:  Open Forum Infect Dis       Date:  2016-08-29       Impact factor: 3.835

7.  Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy.

Authors:  Carmine Rossi; Janet Raboud; Sharon Walmsley; Curtis Cooper; Tony Antoniou; Ann N Burchell; Mark Hull; Jason Chia; Robert S Hogg; Erica E M Moodie; Marina B Klein
Journal:  BMC Infect Dis       Date:  2017-04-04       Impact factor: 3.090

8.  Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD.

Authors:  Haesuk Park; Chao Chen; Wei Wang; Linda Henry; Robert L Cook; David R Nelson
Journal:  Hepatology       Date:  2017-12-23       Impact factor: 17.425

9.  Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK.

Authors:  Benjamin Hudson; Alex J Walker; William L Irving
Journal:  J Med Virol       Date:  2017-08-30       Impact factor: 2.327

10.  Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.

Authors:  Peter Ferenci; Stefan Bourgeois; Peter Buggisch; Suzanne Norris; Manuela Curescu; Dominique Larrey; Fiona Marra; Henning Kleine; Patrick Dorr; Mariem Charafeddine; Eric Crown; Mark Bondin; David Back; Robert Flisiak
Journal:  J Viral Hepat       Date:  2019-03-05       Impact factor: 3.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.